As introduced earlier, we believe that the most significant clinical implication of the tumour sink effect is that, in PSMA RPT, patients with a large tumour burden will likely be undertreated, from a dosimetry perspective, when a fixed activity is administered, such as per the currently approved regime of 177Lu-PSMA-617 [2]. Here, FOLH1 is linked to neoplasm.